Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P English

Showing results (191-200 of 209) with videos related to

Pageof 21
Sort By:
British Journal of Cancer|December 2, 2015
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomasJonathan D Black, Salvatore Lopez, Emiliano Cocco, et al.
British Journal of Cancer|September 2, 2015
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomasJonathan D Black, Salvatore Lopez, Emiliano Cocco, et al.
Cancer Medicine|June 4, 2014
T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivoDiana P English, Stefania Bellone, Carlton L Schwab, et al.
Molecular Cancer Therapeutics|September 4, 2015
Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In VivoSalvatore Lopez, Emiliano Cocco, Jonathan Black, et al.
Elife|April 28, 2020
Live-cell single particle imaging reveals the role of RNA polymerase II in histone H2A.Z evictionAnand Ranjan, Vu Q Nguyen, Sheng Liu, et al.
Cancer|September 25, 2014
Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivoDiana P English, Stefania Bellone, Carlton L Schwab, et al.
British Journal of Cancer|October 1, 2014
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivoC L Schwab, S Bellone, D P English, et al.
Gynecologic Oncology|August 12, 2015
Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivoCarlton L Schwab, Diana P English, Jonathan Black, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|February 12, 2015
Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitroLiancheng Zhu, Salvatore Lopez, Stefania Bellone, et al.
Nature Biotechnology|July 5, 2016
Protein-retention expansion microscopy of cells and tissues labeled using standard fluorescent proteins and antibodiesPaul W Tillberg, Fei Chen, Kiryl D Piatkevich, et al.
Pageof 21

Showing results (191-200 of 209) with videos related to

Sort By:
Pageof 21
British Journal of Cancer|December 2, 2015
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomasJonathan D Black, Salvatore Lopez, Emiliano Cocco, et al.
British Journal of Cancer|September 2, 2015
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomasJonathan D Black, Salvatore Lopez, Emiliano Cocco, et al.
Cancer Medicine|June 4, 2014
T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivoDiana P English, Stefania Bellone, Carlton L Schwab, et al.
Molecular Cancer Therapeutics|September 4, 2015
Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In VivoSalvatore Lopez, Emiliano Cocco, Jonathan Black, et al.
Elife|April 28, 2020
Live-cell single particle imaging reveals the role of RNA polymerase II in histone H2A.Z evictionAnand Ranjan, Vu Q Nguyen, Sheng Liu, et al.
Cancer|September 25, 2014
Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivoDiana P English, Stefania Bellone, Carlton L Schwab, et al.
British Journal of Cancer|October 1, 2014
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivoC L Schwab, S Bellone, D P English, et al.
Gynecologic Oncology|August 12, 2015
Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivoCarlton L Schwab, Diana P English, Jonathan Black, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|February 12, 2015
Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitroLiancheng Zhu, Salvatore Lopez, Stefania Bellone, et al.
Nature Biotechnology|July 5, 2016
Protein-retention expansion microscopy of cells and tissues labeled using standard fluorescent proteins and antibodiesPaul W Tillberg, Fei Chen, Kiryl D Piatkevich, et al.
Pageof 21